Bayer rethinking plastics IPO plans; WHO's new HIV drug guidelines could boost Gilead, GSK;

@FiercePharma: Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer eyes challenge to oral MS meds with new Betaseron injector. Article | Follow @CarlyHFierce

> Bayer and its advisers are rethinking options for the IPO of the company's plastics unit, scheduled for this Friday; books are still not covered, sources told Reuters Wednesday. Report

> The World Health Organization (WHO) is calling for early treatment with anti-retroviral drugs for HIV patients, a push that could give HIV drugmakers like Gilead ($GILD) and GlaxoSmithKline ($GSK) a boost. Report

> Novartis ($NVS) has issued a voluntary recall of an ADHD drug manufactured in Georgia. More

> Pfizer's ($PFE) Wyeth subsidiary will perform nearly $194 million worth of cleanup work at the American Cyanamid Superfund Site in Bridgewater Township, NJ. Report

> The U.S. Patent and Trademark Office (PTO)'s Patent Trial and Appeal Board has, through the inter partes review system, found two patents on Novartis' Exelon Patch to be unpatentable. Release

> Novartis has opened a global data center at its Alcon campus in Fort Worth, TX. More

Medical Device News

@FierceMedDev: Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: OraSure reels in $7.2M from HHS for rapid Ebola test. FierceDiagnostics story | Follow @EmilyWFierce

> Baxter makes nice with activist investor Third Point, offers board seats. Report

> Bard to buy out Medicon, its long-standing Japanese JV with Kobayashi. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Execs behind Imbruvica raise $75M for a new cancer project. News

> Racing AstraZeneca, Clovis gets a speedy FDA review for its lung cancer drug. Story

> Astellas inks a back-loaded $515M deal to get its hands on a pain drug. Article

Biotech Research News

> The contentious gene editing field gets a tech upgrade. What now? Story

> FDA's 'breakthrough' endorsement carries real weight with the public. Report

> Looking for an alternative to pricey Daraprim? You may be in luck. More

> Researchers zero in on immune system's role in Alzheimer's. Story

> A molecule isolated from the depths of the ocean shows promise in treating AML. Article

Diagnostics News

> Diagnostics companies strike back at CMS lab test rule. More

> OraSure reels in $7.2M from HHS for rapid Ebola test. Item

> Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate. Report

> Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. Story

> Quest launches patient analytics tool for healthcare providers. Article

Pharma Marketing News

> Roche poised for MS coup with success in hard-to-treat progressive form. Article

> Looking for the next wave of pharma innovation? Try opening the door to more partners, Accenture says. More

> Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. Story

> New Hampshire AG puts pain drug marketing under his microscope. Item

> JAMA: 'Breakthrough' talk in FDA press releases could unfairly sway consumers. Report

And Finally... More than 15 million people enrolled in the top 10 Medicare Part D prescription drug plans will face average premium hikes of 8% in 2016, a new analysis says. More

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.